Ocugen, Inc.

211 articles about Ocugen, Inc.

• Nature Gene Therapy Publishes Preclinical Data of Ocugen’s OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)

  3/3/2020

  Data support nuclear hormone receptor gene NR2E3 as genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases and potentially serve as a broad-spectrum therapy

• Ocugen to Present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference

  2/10/2020

  Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced it will present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference, to be held February 17-18, 2020 in Hollywood, Florida.

• 

  Clinical Catch-Up: December 9-13

  12/16/2019

  It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.

• Ocugen Announces Completion of 50% of Enrollment of its Phase 3 Clinical Trial for ocular GVHD

  12/9/2019

  Topline data anticipated in second half of 2020

• Ocugen Announces Completion of 50% of Enrollment of its Phase 3 Clinical Trial for ocular GVHDTopline data anticipated in second half of 2020

  12/9/2019

  Ocugen, Inc., (NASDAQ: OCGN), ), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced that it has completed 50% of enrollment of its Phase 3 clinical trial for OCU300 for patients with ocular Graft Versus Host Disease (oGVHD).

• Ocugen Provides Business Update and Third Quarter 2019 Financial HighlightsConference Call and Webcast Today at 8:30 a.m. ET

  11/8/2019

  Ocugen, Inc.,, a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, reported financial highlights for the third quarter of 2019 and a business update.

• Ocugen Announces Warrant Restructuring Reduced Series C warrant shares to 20 million from 50 million

  11/6/2019

  Ocugen, Inc. announced that it has entered into an amendment to each of the warrants issued pursuant to the Securities Purchase Agreement dated June 13, 2019 with certain Investors to restructure each of the warrants held by each such investor.

• Ocugen Announces Appointments to Retina Disease and Ocular Graft-Versus-Host Disease Scientific Advisory Boards

  11/4/2019

  Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced the appointment of retina and ocular Graft-Versus-Host Disease (oGVHD) scientific advisory boards comprised of prominent experts to provide strategic advice, clinical and regulatory support, and scientific and industry expertise.

• Ocugen to Host Conference Call on Friday, November 8 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights

  10/25/2019

  Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced that it will release corporate and financial results for the third quarter that ended September 30, 2019 before the open of the U.S. financial markets on Friday, November 8, 2019

• Ocugen Appoints Jessica Crespo, CPA, as Controller

  10/23/2019

  Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced the appointment of Jessica Crespo, CPA, to the role of Controller, effective October 23, 2019.

• Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics

  9/30/2019

  Ocugen, Inc., announced the completion of its merger with Histogenics Corporation, and the change of the combined company’s name to “Ocugen, Inc.” Ocugen is expected to begin trading on The Nasdaq Capital Market under the ticker symbol “OCGN.” The executive team of Ocugen has become the executive team of the combined company, led by Shankar Musunuri, Ph.D., M.B.A., as Chairman, Chief Executive Officer and Co-Founder.

• Ocugen and CanSinoBIO Enter Strategic Partnership for Gene Therapy Co-Development and Manufacturing

  9/30/2019

  Partnership to develop OCU400, Ocugen’s orphan drug designated gene therapy candidate in its modifier gene therapy platform

• 

  Massachusetts Life Science M&A Hits $22.5 Billion So Far This Year

  7/10/2019

  As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.

• Ocugen Granted FDA Orphan Drug Designation for OCU400 Gene Therapy for the Treatment of NR2E3 Mutation-Associated Retinal Degenerative Disease

  2/14/2019

  Ocugen, Inc. announced the U.S. Food and Drug Administration granted orphan drug designation for OCU400, Ocugen's novel gene therapy, for the treatment of NR2E3 mutation-associated retinal degenerative disease.

• Ocugen to Highlight Phase 2 Clinical Data for OCU310 at AAO 2018

  10/23/2018

  The poster will highlight the tolerability and preliminary efficacy results from a randomized Phase 2 proof-of-concept study in patients with DED.

• Ocugen Initiates Phase 3 Clinical Trial of OCU310 for Dry Eye Disease

  10/1/2018

  Ocugen, Inc. today announced that it has initiated a Phase 3 clinical trial for its second lead product candidate, OCU310 for patients with dry eye disease (DED). 

• Ocugen to Present at Two Upcoming Investor Conferences

  9/26/2018

  Ocugen is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases

• Ocugen Appoints James G. Murphy, CPA, as Chief Financial Officer

  8/13/2018

  Ocugen, Inc. announced the appointment of James G. Murphy, CPA, to the role of Chief Financial Officer.

• Ocugen Initiates Phase 3 Clinical Trial of OCU300 for the Treatment of Ocular Graft Versus Host Disease

  7/2/2018

  Ocugen, Inc. announced that it has initiated the first of two pivotal, Phase 3 clinical trials of OCU300

• Ocugen Presents Preclinical Efficacy Data of its Proprietary Nanoemulsion Technology at ARVO 2018

  5/2/2018

  Ocugen, Inc. announced that it presented additional preclinical findings in a poster highlighting the potential efficacy of its unique, patented nanoemulsion formulation of brimonidine tartrate (OCU300) at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, held April 29 - May 3, 2018, in Honolulu, Hawaii.